IP Verse

Hertin Und Partner Rechts Und Patentanwalte Partg Mbb competitive analysis

Loading summary...

Latest oppositions filed by Hertin Und Partner Rechts Und Patentanwalte Partg Mbb

Explore patent oppositions filed by Hertin Und Partner Rechts Und Patentanwalte Partg Mbb against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3115041
Crush-Resistant Tablets Intended For Preventing Accidental Misuse And Unlawful DiversionETHYPHARMJul 25, 2024
EP2325644
Sequences For Detection And Identification Of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Of Mrej Type XiiBECTON DICKINSON INFUSION THERAPY SYSTEMSApr 29, 2021
EP2325645
Sequences For Detection And Identification Of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Of Mrej Type XiiiBECTON DICKINSON INFUSION THERAPY SYSTEMSApr 29, 2021
EP2568968
Manufacturing Of Active-Free Granules And Tablets Comprising The SameEURO CELTIQUEApr 12, 2018

Latest publications and patents of Hertin Und Partner Rechts Und Patentanwalte Partg Mbb New

Explore the latest publications and patents granted to Hertin Und Partner Rechts Und Patentanwalte Partg Mbb, showcasing their recent innovations and technological advancements.

Latest PTAB cases involving Hertin Und Partner Rechts Und Patentanwalte Partg Mbb

Discover the latest PTAB cases involving Hertin Und Partner Rechts Und Patentanwalte Partg Mbb, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Hertin Und Partner Rechts Und Patentanwalte Partg Mbb with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
HERTIN UND PARTNER RECHTS UND PATENTANWALTE PARTG MBB4 - - -
BECTON DICKINSON INFUSION THERAPY SYSTEMS - 8 - -
ETHYPHARM112 - -
GENEOHM SCIENCES - 8 - -